Drugs / LPV7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02126579 | May 2014 → Nov 2019 | metastatic melanoma, mucosal melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPV7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02126579 ↗ |
| Modality | Vaccine | “We performed a clinical trial to evaluate safety and immunogenicity of a novel long peptide vaccine administered in combinations of incomplete Freund's adjuvant (IFA) and...” PMID 34413169 ↗ Aug 2021 |
| Route | Subcutaneous | “1.5 mL administered half intradermally and half subcutaneously.” NCT02126579 ↗ |